136 related articles for article (PubMed ID: 18356801)
1. A rivastigmine patch for dementia.
Med Lett Drugs Ther; 2008 Mar; 50(1282):21-2. PubMed ID: 18356801
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
Lefèvre G; Sedek G; Jhee SS; Leibowitz MT; Huang HL; Enz A; Maton S; Ereshefsky L; Pommier F; Schmidli H; Appel-Dingemanse S
Clin Pharmacol Ther; 2008 Jan; 83(1):106-14. PubMed ID: 17522596
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Darreh-Shori T; Jelic V
Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
[TBL] [Abstract][Full Text] [Related]
4. [Rivastigmine patch effective for 24 hours. Effective dose, good tolerance, reliable therapeutic effectiveness].
Burian R
MMW Fortschr Med; 2010 Sep; 152(37):40-1. PubMed ID: 21192453
[No Abstract] [Full Text] [Related]
5. Rivastigmine exposure provided by a transdermal patch versus capsules.
Mercier F; Lefèvre G; Huang HL; Schmidli H; Amzal B; Appel-Dingemanse S
Curr Med Res Opin; 2007 Dec; 23(12):3199-204. PubMed ID: 18001519
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic rationale for the rivastigmine patch.
Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
Sadowsky CH; Farlow MR; Meng X; Olin JT
Int J Clin Pract; 2010 Jan; 64(2):188-93. PubMed ID: 20089009
[TBL] [Abstract][Full Text] [Related]
8. Rivastigmine in Parkinson's disease dementia.
Lalli S; Albanese A
Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
[TBL] [Abstract][Full Text] [Related]
9. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
[TBL] [Abstract][Full Text] [Related]
10. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
Schmidt R; Alf C; Bancher C; Benke T; Berek K; Dal-Bianco P; Führwürth G; Imarhiagbe D; Jagsch C; Lechner A; Rainer M; Reisecker F; Rotaru J; Uranüs M; Walter A; Winkler A; Wuschitz A
Neuropsychiatr; 2009; 23(1):58-63. PubMed ID: 19272293
[TBL] [Abstract][Full Text] [Related]
11. Rivastigmine patches: line extension. No therapeutic advantage and less convenient than capsules.
Prescrire Int; 2009 Feb; 18(99):19. PubMed ID: 19391277
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application.
Lefèvre G; Sedek G; Huang HL; Saltzman M; Rosenberg M; Kiese B; Fordham P
J Clin Pharmacol; 2007 Apr; 47(4):471-8. PubMed ID: 17389556
[TBL] [Abstract][Full Text] [Related]
13. Rivastigmine: new indication. Dementia and Parkinson's disease: no thank you!
Prescrire Int; 2007 Apr; 16(88):66. PubMed ID: 17458048
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.
Lefèvre G; Pommier F; Sedek G; Allison M; Huang HL; Kiese B; Ho YY; Appel-Dingemanse S
J Clin Pharmacol; 2008 Feb; 48(2):246-52. PubMed ID: 18199897
[No Abstract] [Full Text] [Related]
15. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
[TBL] [Abstract][Full Text] [Related]
16. Rivastigmine and Parkinson dementia complex.
Moretti R; Torre P; Vilotti C; Antonello RM; Pizzolato G
Expert Opin Pharmacother; 2007 Apr; 8(6):817-29. PubMed ID: 17425477
[TBL] [Abstract][Full Text] [Related]
17. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.
Blesa R; Ballard C; Orgogozo JM; Lane R; Thomas SK
Neurology; 2007 Jul; 69(4 Suppl 1):S23-8. PubMed ID: 17646620
[TBL] [Abstract][Full Text] [Related]
18. Rivastigmine for dementia associated with Parkinson's disease.
Morgan J; Sethi KD
Curr Neurol Neurosci Rep; 2005 Jul; 5(4):263-5. PubMed ID: 15987609
[No Abstract] [Full Text] [Related]
19. Maculopapular eruption to rivastigmine's transdermal patch application and successful oral desensitization.
Makris M; Koulouris S; Koti I; Aggelides X; Kalogeromitros D
Allergy; 2010 Jul; 65(7):925-6. PubMed ID: 19889118
[No Abstract] [Full Text] [Related]
20. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch.
Lefèvre G; Büche M; Sedek G; Maton S; Enz A; Lorch U; Sagan C; Appel-Dingemanse S
J Clin Pharmacol; 2009 Apr; 49(4):430-43. PubMed ID: 19246725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
